Richard S. Lindahl - 21 Feb 2024 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Chief Financial Officer
Signature
/s/ Jennifer Lynne Fox, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
21 Feb 2024
Net transactions value
-$12,289
Form type
4
Filing time
27 Feb 2024, 20:26:40 UTC
Previous filing
14 Feb 2024
Next filing
04 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Disposed to Issuer $10,873 -4,012 -2.3% $2.71 168,980 21 Feb 2024 Direct F1
transaction EBS Common Stock Tax liability $1,417 -517 -0.31% $2.74 168,463 23 Feb 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. On February 21, 2024, the final certification date, the Compensation Committee certified the achievement of the 2021-2023 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 4,012 shares previously reported on February 24, 2021.
F2 Represents shares of common stock withheld to pay taxes.

Remarks:

This Form 4 was filed late due to an inadvertent administrative error. The Company will report all late Form 4s in its next proxy statement